135 related articles for article (PubMed ID: 179712)
1. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes.
Cox PJ; Phillips BJ; Thomas P
Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712
[TBL] [Abstract][Full Text] [Related]
2. The enzymatic basis of the selective action of cyclophosphamide.
Cox PJ; Phillips BJ; Thomas P
Cancer Res; 1975 Dec; 35(12):3755-61. PubMed ID: 172233
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
Brock N
Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
[TBL] [Abstract][Full Text] [Related]
5. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.
Kohn FR; Landkamer GJ; Manthey CL; Ramsay NK; Sladek NE
Cancer Res; 1987 Jun; 47(12):3180-5. PubMed ID: 3034402
[TBL] [Abstract][Full Text] [Related]
6. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
7. Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification.
Manthey CL; Landkamer GJ; Sladek NE
Cancer Res; 1990 Aug; 50(16):4991-5002. PubMed ID: 2379164
[TBL] [Abstract][Full Text] [Related]
8. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
10. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
11. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
12. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
13. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
Hohorst HJ; Draeger U; Peter G; Voelcker G
Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
[TBL] [Abstract][Full Text] [Related]
14. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
Manthey CL; Sladek NE
Biochem Pharmacol; 1988 Jul; 37(14):2781-90. PubMed ID: 3395357
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
16. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
17. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
Peter G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
[TBL] [Abstract][Full Text] [Related]
18. The use of deuterated analogs in qualitative and quantitative investigations of the metabolism of cyclophosphamide (NSC-26271).
Cox PJ; Farmer PB; Foster AB; Gilby ED; Jarman M
Cancer Treat Rep; 1976 Apr; 60(4):483-91. PubMed ID: 1277225
[TBL] [Abstract][Full Text] [Related]
19. Aldophosphamide: synthesis, characterization, and comparison with "Hohorst's aldophosphamide".
Struck RF
Cancer Treat Rep; 1976 Apr; 60(4):317-9. PubMed ID: 1277207
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
